Abstract 912: CheckpointPx, an interpretable radiology AI tool, predicts checkpoint blockade benefit independent of PDL1 status in non-small cell lung cancers (NSCLC): A multi-institutional validation study
Amogh Hiremath(Ohio Department of Health), Young Kwang Chae(Northwestern University), Leeseul Kim, Trie Arni Djunadi(Richmond University Medical Center), Liam Il‐Young Chung(Northwestern University), Hye Sung Kim(Northwestern University), Anant Madabhushi(Emory University), Jisang Yu(St. Rose Dominican Hospital), Cecilia Nam(Northwestern University), Yuchan Kim(Northwestern University), Amit Gupta(University of Washington), Sungmi Yoon(Northwestern University), Yury Velichko(Northwestern University), Vamsidhar Velcheti(Cleveland Clinic), Ilene Hong(Northwestern University), Monica Yadav(Northwestern University), Maria Jose Aguilera Chuchuca(Northwestern University), Nathaniel Braman(Tempus Labs (United States)), Youjin Oh(Kookmin University), Taegyu Um(Northwestern University), Kai Zhang(Capital Medical University), Jeeyeon Lee(Northwestern University), Seyoung Lee(Johns Hopkins University), Soowon Lee(Johns Hopkins University), Peter Haseok Kim(The University of Texas at Austin), Zunairah Shah(Roswell Park Comprehensive Cancer Center), Grace Kang(Northwestern University), Timothy Hong(Northwestern University), Jessica Jang(Northwestern University), Myungwoo Nam(Lincoln Medical Center), Salie Lee(Johns Hopkins University), Amy Cho(Northwestern University)
Cited by 2
Related Papers
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
|Nature Reviews Clinical Oncology|2021|810
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537